Engaged in the R&D of complex pharmaceutical formulations, Lianya Pharmaceutical (301569.SZ) plans to launch an IPO on the ChiNext Board.

Zhitong Finance APP News, Lianya Pharmaceutical (301569.SZ) has released its prospectus intent for the initial public offering and listing on the ChiNext board. The number of shares to be publicly issued this time is 133,739,563 shares, accounting for 15% of the total share capital after issuance. The preliminary price inquiry date is September 22, 2026, and the subscription date is September 28, 2026. The initial strategic placement in this issuance is 40,121,868 shares, accounting for approximately 30.00% of this issuance. Among them, the special asset management plan established by the issuer's senior management and core employees participating in this strategic placement is expected to subscribe no more than 10.00% of this issuance, i.e., no more than 13,373,956 shares, and the subscription amount shall not exceed RMB 31.30 million; the total subscription amount of other investors participating in the strategic placement shall not exceed RMB 30 million; the initial co-investment by the sponsor's relevant subsidiary is approximately 5.00% of this issuance, i.e., 6,686,978 shares.